Please assess the completion status of the following clinical trial:

Trial Title: Indigo Naturalis in Treating Atopic Dermatitis Topically

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Between 6 and 65 years old, female or male.~2. Atopic dermatitis fulfilling the diagnostic criteria of Williams et al.~3. Atopic dermatitis involving \<40% of BSA. (Base on the BSA result of Screening)~4. An Investigator's Global Assessment (IGA) score of 2, 3 or 4 which corresponds to mild, moderate or severe disease. (Base on the IGA result of Screening)~5. Female patients of child-bearing age with negative pregnancy test at screening.~6. Female patients of child-bearing age that agree to continue using birth control measures approved by the investigator and agree not to lactate for the duration of the study.~7. Agree to only receive stable doses of an additive-free, basic bland emollient for at least 7 days before baseline (day0)~8. Willing to comply with study protocol and agree to sign an informed consent form.~Exclusion Criteria:~1. Having a history of topical or systematical hypersensitivity to indigo naturalis or its excipient (e.g. beeswax) in ointment~2. Undergoing phototherapy (e.g. UVB, PUVA) or systemic therapy (e.g. Immunosuppressive agents) within 30 days.~3. Having used topical therapy (e.g. topical corticosteroids) for dermatitis within 7 days before the first application of the study medication.~4. Having a significant concurrent disease, such as: significant abnormalities in hematology, severe uncontrolled metabolic syndrome (e.g., hypertension, diabetes mellitus, metabolic arthritis, hyperthyroidism), psychiatric disease, cancer or AIDS.~5. Having abnormal liver or renal function (AST/ALT \>3 x ULN, creatinine \>2.0 mg/dl).~6. Women who are lactating, pregnant or preparing to be pregnant.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Indigo naturalis ointment (Type: EXPERIMENTAL): 1. Form: ointment~2. Dose: each gram of ointment contains 200µg of indirubin~3. Dosing schedule: apply 0.5g of ointment per 10 x 10 dermatitis lesion twice daily
- Placebo (Type: PLACEBO_COMPARATOR): 1. Form: ointment~2. Dose: vehicle~3. Dosing schedule: apply 0.5g of ointment per 10 x 10 dermatitis lesion twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).